Oneness Biotech Co., Ltd.

Taipei Exchange:4743.TWO

Sector

🏥 Health Care

Industries

🔬 Clinical Trials

🧬 Biotechnology

💊 Pharmaceuticals

Location

Taiwan

Market Cap

USD 1.08 B

Share Price

USD 2.26

Avg Daily Volume

2,132,457

Change (1 day)

-5.17%

Change (1 year)

-49.16%

Change (YTD)

-14.87%

Oneness Biotech Co., Ltd. Accounts Payable for the year ending December 31, 2024: USD 83.17 K

Oneness Biotech Co., Ltd. Accounts Payable is USD 83.17 K for the year ending December 31, 2024, a 49.93% change year over year. Accounts payable are amounts owed by the company to suppliers or vendors for goods or services received but not yet paid.

Oneness Biotech Co., Ltd. Accounts Payable for the year ending December 31, 2023 was USD 55.47 K, a 20.44% change year over year.
Oneness Biotech Co., Ltd. Accounts Payable for the year ending December 31, 2022 was USD 46.06 K, a -26.79% change year over year.
Oneness Biotech Co., Ltd. Accounts Payable for the year ending December 31, 2021 was USD 62.91 K, a -96.35% change year over year.
Oneness Biotech Co., Ltd. Accounts Payable for the year ending December 31, 2020 was USD 1.72 M, a 16,621.43% change year over year.

Quarterly
Annual
TTM

From:

To:

Zoom:

Key data

Date	Accounts Payable	Short-Term Debt	Long-Term Debt	Total Liabilities

Taipei Exchange: 4743.TWO

Oneness Biotech Co., Ltd.

CEO	Mr. Nien-Yi Chen
IPO Date	Sept. 23, 2011
Location	Taiwan
Headquarters	No.236, Xinyi Road
Employees	180
Sector	🏥 Health Care
Industries Clinical Trials 🧬 Biotechnology 💊 Pharmaceuticals

Description

Oneness Biotech Co., Ltd engages in the research and development of new drugs, and sale of pharmaceutical and health products in Taiwan. It operates through New Drug Research and Development, and Agricultural Products Cultivation segments. The company develops ON101, which is in Phase III clinical trials for treating chronic diabetic foot ulcers; and OB318, an anti-cancer drug that is in Phase I clinical trials. It is also developing FB704A that has completed Phase I clinical trial for the treatment of rheumatoid arthritis and systemic sclerosis; FB825, which is in Phase II clinical trial for treating atopic dermatitis, allergic diseases, and asthma; and FB918, a human monoclonal antibody, which is in pre-clinical stage for the treatment of allergic asthma. In addition, the company engages in the management of agriculture cultivation and trading business; and sale of agricultural products. The company was incorporated in 2008 and is headquartered in Taipei City, Taiwan.